Helena Martínez

Helena Martínez

Auto-generated profile, based on publicly available information

Helena Martínez

Laboratorio Reig Jofre, S.A. Barcelona Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2024 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
PDF file
RLRaul De Lucas
Raul De Lucas
HMHelena Martínez
Helena Martínez
CNCarlos Nieto
Carlos Nieto
CRCarlos Ruiz‐Alonso
Carlos Ruiz‐Alonso
RBRafael Bermejo
Rafael Bermejo
MPMontse Pérez
Montse Pérez
Objectives: Dysbiosis of the skin microbiota has been identified as a key factor in the development of acne. This study was aimed to evaluate the effect of a facial cream gel containing a biotechnological phytocomplex, niacinamide and succinic acid on the bacterial diversity of subjects with mild–moderate acne and its clinical benefits due to microbiota changes.Methods: Open‐label, clinical study in 44 subjects with mild–moderate acne treated with a facial cream gel for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated using the IGA acne severity scale, biometric measurements, and safety.Results: After 56 days of product's use, an increase in alpha and beta diversity was found (p < 0.01), with a decrease in the relative abundance of C. acnes (48.99% vs. 38.83%, p < 0.001). Regarding clinical results, a decrease in acne severity on the IGA scale (27.33%, p < 0.001), number of non‐inflammatory and inflammatory lesions (respectively: 31.12%, p = 0.05; 47.27%, p < 0.001), amount of sebum (89.00%, p < 0.01) and erythema (15.35%, p < 0.01), was found. [Correction added on 19 September 2024, after first online publication: In the preceding sentence, “42.27%” has been changed to “47.27%” in this version.] Responder analysis of the IGA score showed that 61.36% of patients improved by at least one point at day 56. The product was well tolerated throughout the study.Conclusions: The use of the facial cream gel on skin was effective in rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing the number of mild–moderate acne lesions and sebum secretion, and consequently improving acne's severity.

17 November 2022 in Mycoses
Verified
Journal Article
Open access
AZAntonio Zalacain-Vicuña
Antonio Zalacain-Vicuña
CNCarlos Nieto
Carlos Nieto
JPJordi Picas
Jordi Picas
HMHelena Martínez
Helena Martínez
RBRafael Bermejo
Rafael Bermejo
VBVicente Garcia-Patos Briones
Vicente Garcia-Patos Briones
Background: A new water‐soluble formulation with ciclopirox has shown a higher penetration than other ciclopirox nail lacquers currently marketed, thus providing a higher concentration of ciclopirox into the nail.Objective: To evaluate the efficacy and safety of a new ciclopirox nail hydrolacquer compared with its vehicle and an active comparator (hydroxypropyl chitosan‐based 80 mg/g ciclopirox nail lacquer) for the treatment of toenail fungal infection.Methods: Phase III, multicenter, randomised, double‐blind, clinical trial in patients with distal mild to moderate toenail onychomycosis due to dermatophyte fungi. Patients were randomised to apply topically a ciclopirox nail hydrolacquer, its vehicle or a reference product once daily for 48 weeks with a follow‐up period of 4 weeks up to week 52.Results: A total of 381 patients were included. No statistically significant differences were observed between patient groups in the proportion of subjects achieving a complete cure. At week 52, a higher percentage of patients in the ciclopirox nail hydrolacquer group achieved a mycological cure (negative for culture and DTS/KOH test, with results: 32.0% ciclopirox nail hydrolacquer, 23.2% vehicle and 27% reference product, respectively), and similar results were found for improvement (mycological cure and reduction of diseased nail ≥20%, with results: 27.2% ciclopirox nail hydrolacquer, 21.6% vehicle and 20.6% reference product, respectively). Regarding mycological results, only ciclopirox nail hydrolacquer demonstrated significant statistical superiority versus vehicle negativizing dermatophyte culture (p = .039) with no recurrences, relapses or re‐infections in a four‐week follow‐up patients with complete cure. The safety profile was comparable to the vehicle and reference product and consistent with the previously reported.Conclusions: A new water‐soluble formulation for a ciclopirox nail lacquer showed similar efficacy to the reference product to eradicate toenail onychomycosis and superiority in the mycological cure defined by negative culture, thus preventing reinfections and recurrences. Efficacy and safety data demonstrate the positive benefit–risk profile of this new topical antifungal preparation. [Correction added on 13 April 2023, after first online publication: The results and conclusions in the Abstract contained incorrect information and were revised in this version.]

23 July 2024 in Skin Research and Technology
Verified
Journal Article
Open access
PDF file
AGAurora Guerra‐Tapia
Aurora Guerra‐Tapia
HMHelena Martínez
Helena Martínez
CNCarlos Nieto
Carlos Nieto
CACarlos Ruiz Alonso
Carlos Ruiz Alonso
RBRafael Bermejo
Rafael Bermejo
RLRaul De Lucas
Raul De Lucas
Background: The disruption of the microbial community or dysbiosis alters the functional composition, metabolic activity, and local distribution of the microbiota leading the development of acne. The aim of this study is to evaluate the effect of a lotion containing a biotechnological phytocomplex, niacinamide, and succinic acid in the bacterial diversity of subjects with truncal mild‐moderate acne and its clinical benefits due to microbiota changes. Materials and Methods: Open, clinical study in 43 subjects with truncal mild‐moderate acne treated with a lotion for 8 weeks. Bacterial diversity was analyzed by 16S rRNA gene sequencing of skin samples. Clinical effects were evaluated through IGA acne severity scale, biometric measurements, and safety. Results: After 56 days of product's use, an increase in richness alpha diversity was found ( p = 0.005), with a decrease in Cutibacterium acnes relative abundance (66.43% vs. 58.11%, p = 0.009). The clinical results showed a decrease in IGA score (27.59% decrease; p = 0.001), the inflammatory lesions (52.12% decrease, p = 0.006) and erythema (18.33% decrease, p = 0.007), and desquamation index (63.83% decrease, p = 0.02). The responder analysis of the IGA score showed that 60.47% of patients improved by at least one point at day 56. The product was well tolerated along the study. Conclusion: The use of the lotion on acneic skin was effective on rebalancing the microbiota, inhibiting biofilm formation and other virulence factors, reducing erythema and desquamation, and improving acne's severity.